Protega

Pharma

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 1 drug with upcoming expirations

Activity

Key Events

Apr 20, 2017FDAOxyContin — ROXYBOND

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

4 patent groups across drugs · Source: FDA Orange Book

DrugExpires

OxyContin9 patentsAug 24, 2027 OxyContin2 patentsAug 12, 2028 OxyContin4 patentsMar 29, 2030 OxyContin4 patentsSep 2, 2036

Regulatory

Regulatory Timeline

19981 event

FDAOct 26

OxyContin — ROXICODONE

Application NDA020932 (NDA)

20091 event

FDAMay 15

OxyContin — ROXICODONE

Application NDA021011 (NDA)

20102 events

FDAOct 20

OxyContin — OXYCODONE HYDROCHLORIDE

Application NDA200534 (NDA)

FDAApr 5

OxyContin — OXYCONTIN

Application NDA022272 (NDA)

20111 event

FDAJun 17

OxyContin — OXAYDO

Application NDA202080 (NDA)

20121 event

FDAJan 12

OxyContin — OXYCODONE HYDROCHLORIDE

Application NDA201194 (NDA)

20131 event

FDAAug 22

OxyContin — OXYCODONE HYDROCHLORIDE

Application NDA200535 (NDA)

20161 event

FDAApr 26

OxyContin — XTAMPZA ER

Application NDA208090 (NDA)

20171 event

FDAApr 20

OxyContin — ROXYBOND

Application NDA209777 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)